Standard quality fully bound wood shell with black vinyl covering, black plush-lined interior and adjustable foam blocks to fit any bass clarinet designed to disassemble into 5 pieces. Large accessory compartment with lid, 2 nickel-plated draw type latches and 3 hinges. Models for 1-piece or 5-piece... Apr 14, 2018- Explore gay's board "idk coool stuff" on Pinterest. See more ideas about Bass clarinet, Ideas for drawing and Music.
Bass Clarinet Music Van Cott Information Services Inc.
Awesome Bass Clarinet Mouthpiece Comparison Chart Portraits – Admin accumulates several types of charts. The document functions to go into detail the data that individuals have.
We did something a bit unusual with the bass clarinet multiphonics, notating the bottom pitch in the bass clef and the top line an octave lower: normally I am very pro treble clef for everything bass clarinet, and pro ledger line, but the sheer number of pitches and ledger lines on each side of the staff made this rather impossible.


Conservation officers enforce laws that control the use of our fish and wildlife. They make sure that people who hunt or fish for recreation or who take fish or wildlife to sell do so according to all the laws. This includes making sure people have proper licenses. These officers also work to protect endangered species and make sure that people do not pollute our waters. Conservation officers work for local, state, or federal government agencies. Most conservation officers in Texas have a bachelor's degree and special law enforcement training.


Design can really make or break your website. Luckily for you, our skilled web designers know all the ins and outs, and will work with you to make your website visions a reality. A well-designed website helps to make your business appear trustworthy and welcoming.
It'll be different if you're a carpenter, run a beauty salon or an accountancy firm. Some visitors might want something that's visually inviting. Others get their attention caught by something more simple or text-oriented.
With Waimea Business, we help you choose and customise the design that makes your business appear as best as possible to your target audience.


text:
High Thoughts
High Reads: A Short History of Nearly Everything
Posted by Ben
As pleasurable as it is to watch movies like Pineapple Express for a good laugh, especially when you're stoned, the world we think we know is as mysterious as it is fascinating. Many of us grimace at the idea of picking up a good book to read high. You're bound to forget everything by morning or fall asleep a page in, so why bother?
Why read a Short History of Nearly Everything?
Whether you decide to blaze beforehand or not is up to you but we highly recommend reading a Short History of Nearly Everything by Bill Bryson. Although written back in 2003 this book covers the history (that we know) of the origins of the earth, universe and scientific thought.
If you like smoking a euphoric, uplifting strain like Jack Herer you've probably felt inspired, boundless creativity that gives you a deeper curiosity and appreciation for everything around you that makes you wonder why you're here. The greatest minds also grappled with this question in their search for knowledge to better understand the cosmos. We've included the craziest quotes and insights from Byron's engrossing science book that will surely blow your mind about your existence and life itself.
TV static is a remnant from the Big Bang
TV static remnant of the Big Bang (Source: Patrick Tomasso)
"Tune your television to any channel it doesn't receive and about 1 percent of the dancing static you see is accounted for by this ancient remnant of the Big Bang. The next time you complain that there is nothing on, remember that you can always watch the birth of the universe."
We are atomic dust
If an apple was magnified to the size of earth, an atom would be the size of the original apple (Source: Roksolana Zasiadko)
"It is a slightly arresting notion that if you were to pick yourself apart with tweezers, one atom at a time, you would produce a mound of fine atomic dust, none of which had ever been alive but all of which had once been you."
We have 30 hydrogen bombs of energy locked inside us
Hydrogen bomb (Source: Business Insider)
"You may not feel outstandingly robust, but if you are an average-sized adult you will contain within your modest frame no less than 7 X 10^18 joules of potential energy—enough to explode with the force of thirty very large hydrogen bombs, assuming you knew how to liberate it and really wished to make a point."
Humans think we are the center of the universe but we aren't even at the center of Earth's history
Earth (Source: NASA Solar System Exploration)
"If you imagine the 4,500-billion-odd years of Earth's history compressed into a normal earthly day, then life begins very early, about 4 A.M., with the rise of the first simple, single-celled organisms…Humans emerge one minute and seventeen seconds before midnight."
Aliens would see Thomas Jefferson and the French Revolution today
Declaration of Independence 1776 (Source: Smithsonian Magazine)
"We may be only one of millions of advanced civilizations. Unfortunately, space being spacious, the average distance between any two of these civilizations is reckoned to be at least two hundred light-years, which is a great deal more than merely saying it makes it sound. It means for a start that even if these beings know we are here and are somehow able to see us in their telescopes, they're watching light that left Earth two hundred years ago."
We are currently in an ice age
Ice Age movie (Source: Plugged In)
"For most of its history until fairly recent times the general pattern for Earth was to be hot with no permanent ice anywhere. The current ice age—ice epoch really—started about forty million years ago, and has ranged from murderously bad to not bad at all."
We wrongly think we're invincible
Tom Hanks in Castaway (Source: Reddit)
"99.99 percent of all species that have ever lived are no longer with us." The most dramatic extinction was the Permian extinction which killed off at least 95% of all species but the cause is unknown. The meteorite that wiped out the dinosaurs was 100 million megatons, the equivalant to a Hiroshima-sized bomb for every human alive.
We are very lucky to be alive
"Not one of your pertinent ancestors was squashed, devoured, drowned, starved, stranded, stuck fast, untimely wounded, or otherwise deflected from its life's quest of delivering a tiny charge of genetic material to the right partner at the right moment in order to perpetuate the only possible sequence of hereditary combinations that could result — eventually, astoundingly, and all too briefly — in you."
The human body is crazy
There are 20 million kilometers of coiled DNA in a human body.
You would instantly vanish if in a meteor's path
Meteorite hits earth (Source: Independent)
"An asteroid or comet traveling at cosmic velocities would enter the Earth's atmosphere at such a speed that the air beneath it couldn't get out of the way and would be compressed, as in a bicycle pump. As anyone who has used such a pump knows, compressed air grows swiftly hot, and the temperature below it would rise to some 60,000 Kelvin, or ten times the surface temperature of the Sun."
Most discoveries took decades even centuries to be recognized
"There are three stages in scientific discovery. First, people deny that it is true, then they deny that it is important; finally they credit the wrong person."
Even Einstein was ignored
Einstein smoking pipe (Source: New Scientist)
Albert Einstein's papers on E=mc2 which got him so much acclaim, didn't land him a job as a university lecturer or even a high school teacher.
We don't know anything
"The upshot of all this is that we live in a universe whose age we can't quite compute, surrounded by stars whose distances we don't altogether know, filled with matter we can't identify, operating in conformance with physical laws whose properties we don't truly understand."
Don't get too hung up on finding meaning when life just is
What is the meaning of life? (Source: Medium)
"It is easy to overlook this thought that life just is. As humans we are inclined to feel that life must have a point. We have plans and aspirations and desires. We want to take constant advantage of the intoxicating existence we've been endowed with. But what's life to a lichen? Yet its impulse to exist, to be , is every bit as strong as ours-arguably even stronger. If I were told that I had to spend decades being a furry growth on a rock in the woods, I believe I would lose the will to go on. Lichens don't. Like virtually all living things, they will suffer any hardship, endure any insult, for a moment's addition to existence. Life, in short, just wants to be."
Live like there's no tomorrow
Just play (Source: Leo Rivas)
It's very clear that we don't know anything about anything. The little we do know was achieved by some of the greatest minds in human history and even thinkers as great as Einstein were initially ignored. What we do know is that life is very short, that we often spend too much time judging ourselves and others, too much time on social media and not enough time just being.
We've been extremely lucky to have even made it to this point and should enjoy life to the fullest without worrying about the past or future too much. Modern society can make us crazy but knowing how lucky we are and how little most things matter in the larger scheme of things puts life into a different, perhaps more encouraging perspective. To close: "Behaviorally modern human beings– that is, people who can speak and make art and organize complex activities– have existed for only about 0.0001 percent of Earth's history. But surviving for even that little while has required a nearly endless string of good fortune." We are very fortunate, indeed.
More high thoughts and books to read high to come!
High Reads: Sapiens
Reading high sounds like a good challenge now that you've got couch lock, right? If you're like most people, you probably forget what...

redpajama_set_name: RedPajamaCommonCrawl


Absolute Brand offers brand valuation services. The company ensures that its associates get excellent brand imaging in their respective categories. The company offers all spectrums of services to do the needful. In addition, Absolute Brand also specializes in sports valuation services for sports franchises.


.685" Lift Dual Spring Kit for LS7 engines using limited stock rocker arm setups and Roller Rockers. Includes dual springs, matching titanium retainers, your choice of locators for Stock or bronze guides, locks and seals.
Spring specs are 170 lbs @ 1.800", 380 lbs @ 1.180", 450 lbs @ 1.115, coil bind @ 1.000" This is a drop in spring kit for all 15 degree LS7 heads.


text:
Q: RSS generator with caching function Do you happen to know any good rss generator script with caching function. All the script I have found over the net so far doesn't support caching! I need the the content of rss to be generated automatically from database in a specified period of time.
Thanks in advance

A: First, to add caching to the script, it seems like it wouldn't be too hard to put Zend_Feed and Zend_Cache together - or just wrap your current generation script with Zend_Cache.
Just setup the cache with your lifetime:
$frontendOptions = array(
  'lifetime' => 7200, // cache lifetime of 2 hours
  'automatic_serialization' => true
);

Then check if the cache is still valid:
if(!$feed = $cache->load('myfeed')) {
  //generate feed
  $cache->save($feed, 'myfeed');
}

//output $feed

I don't know how you form your RSS, but you can import an array structure to Zend_Feed:
$rssFeedFromArray = Zend_Feed::importArray($array, 'rss');

Of course the best way may be to just use your current feed generator and save the output to a file. Use that file as the RSS feed, then use cron/web hooks/queue/whatever to generate the static file. That would be simpler, and use less resources, than having the generation script do the caching.
//feedGen.php
//may require some output buffering if the feed generator outputs directly
$output = $myFeedGenerator->output();
file_put_contents('feed.rss', $output);

Now the feed link is /feed.rss, and you just run feedGen.php whenever it needs to be refreshed. Serving the static file (not even parsed by php) means less for your server to do.

redpajama_set_name: RedPajamaStackExchange


Our 23-minute film, "Tremors in the System: the help you want or the help you get", which we made in collaboration with mental health advocate and psychiatric survivor Marj Berthold, is about her experiences in the mental health system. Ronald Bassman says about the film: "Tremors in the System does what excellent films do best - it helps us understand by inspiring us to feel the struggles and the emotions that are portrayed on screen. The viewer is exposed to the frustrations of being a person living with an extensive psychiatric history who is unable to attain credibility despite all her attempts to communicate her very genuine concerns. I recommend this documentary to stimulate discussion for schools and community groups interested in gaining more understanding of mental illness" Ronald Bassman, Ph.D., author of A Fight to Be: A Psychologist's Experience from Both Sides of the Locked Door .
We are currently developing a feature documentary about the mental health system and issues around forced treatment.


The winners of the 2016 CIPD People Management Awards were announced last night at a glittering awards ceremony at the Grosvenor House Hotel, hosted by actor and comedian Stephen Mangan.
Delivered by the CIPD, the professional body for HR and people development, in partnership with People Management magazine, the awards are the most prestigious in the industry, celebrating outstanding achievement in people management and learning development, and the valuable contribution that HR and L&D professionals make to the overall success of an organisation.
The awards were divided into 19 categories and were open to all types of organisation, regardless of size or sector. Frimley Health NHS Foundation Trust were crowned category winners of the best employee engagement initiative and overall winners for their campaign to improve patient safety and experience at Wexham Park Hospital. The campaign was launched to tackle insufficiencies in organisational culture, performance management and elements of employee behaviour at Wexham Park. Frimley Health initiated a programme of clear and well-structured HR-led interventions that spanned a wide range of areas, from culture and leadership to reward and customer service. The judges agreed that the project was a great example of extremely ambitious and comprehensive organisational transformation, reflected in the CQC's rating of Wexham Park Hospital changing from 'inadequate' to 'outstanding' earlier in the year.
Commenting on the awards, Peter Cheese, Chief Executive at the CIPD, said: "As we celebrated a remarkable twenty years of the CIPD People Management Awards last night, it's clear that the variety and creativity that organisations present every year has only grown over time. 2016 has been a year of great change, and it's fantastic to see HR teams stepping up to new challenges and being so innovative in their approaches to people management and development that are having a lasting impact on businesses.
The headline sponsor for this year's Awards was Resource Management and category sponsors included Cascade, CIPHR, CoreHR, HSBC, Team London and VitalityHealth.


text:
Efficacy and Safety of the Once-Daily GLP-1 Receptor Agonist Lixisenatide in Monotherapy
A randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes (GetGoal-Mono)
Vivian A. Fonseca, MD1⇓,
Ricardo Alvarado-Ruiz, MD2,
Denis Raccah, MD3,
Gabor Boka, MD4,
Patrick Miossec, MD5,
John E. Gerich, MD6 and
on behalf of the EFC6018 GetGoal-Mono Study Investigators
1Department of Medicine, Tulane University Health Sciences Center, New Orleans, Louisiana
2Cardioprevent, Durango, Mexico
3Department of Diabetology, University Hospital Sainte Marguerite, Marseille, France
4Sanofi R&D, Chilly-Mazarin, France
5Sanofi R&D, Paris, France
6Department of Medicine, University of Rochester School of Medicine, Rochester, New York
Corresponding author: Vivian A. Fonseca, vfonseca{at}tulane.edu.
Diabetes Care 2012 Jun; 35(6): 1225-1231. https://doi.org/10.2337/dc11-1935
OBJECTIVE To assess efficacy and safety of lixisenatide monotherapy in type 2 diabetes.
RESEARCH DESIGN AND METHODS Randomized, double-blind, 12-week study of 361 patients not on glucose-lowering therapy (HbA1c 7–10%) allocated to one of four once-daily subcutaneous dose increase regimens: lixisenatide 2-step (10 μg for 1 week, 15 μg for 1 week, and then 20 μg; n = 120), lixisenatide 1-step (10 μg for 2 weeks and then 20 μg; n = 119), placebo 2-step (n = 61), or placebo 1-step (n = 61) (placebo groups were combined for analyses). Primary end point was HbA1c change from baseline to week 12.
RESULTS Once-daily lixisenatide significantly improved HbA1c (mean baseline 8.0%) in both groups (least squares mean change vs. placebo: −0.54% for 2-step, −0.66% for 1-step; P < 0.0001). Significantly more lixisenatide patients achieved HbA1c <7.0% (52.2% 2-step, 46.5% 1-step) and ≤6.5% (31.9% 2-step, 25.4% 1-step) versus placebo (26.8% and 12.5%, respectively; P < 0.01). Lixisenatide led to marked significant improvements of 2-h postprandial glucose levels and blood glucose excursions measured during a standardized breakfast test. A significant decrease in fasting plasma glucose was observed in both lixisenatide groups versus placebo. Mean decreases in body weight (∼2 kg) were observed in all groups. The most common adverse events were gastrointestinal—nausea was the most frequent (lixisenatide 23% overall, placebo 4.1%). Symptomatic hypoglycemia occurred in 1.7% of lixisenatide and 1.6% of placebo patients, with no severe episodes. Safety/tolerability was similar for the two dose regimens.
CONCLUSIONS Once-daily lixisenatide monotherapy significantly improved glycemic control with a pronounced postprandial effect (75% reduction in glucose excursion) and was safe and well tolerated in type 2 diabetes.
In recent years, the use of glucagon-like peptide 1 (GLP-1) receptor agonists has become established as an important therapeutic option in the management of patients with type 2 diabetes (1,2). As a class, GLP-1 receptor agonists possess a number of favorable clinical characteristics in addition to their glucose-lowering effects, including a low propensity to cause hypoglycemia (as a result of their glucose-dependent action) and promotion of weight loss (3,4). Preclinical studies using in vitro and animal models also suggest that GLP-1 receptor agonists have the potential to preserve pancreatic islet β-cells, which may help to provide more stable metabolic control long term (5). As of today, three representatives of the GLP-1 receptor agonist class have been marketed: exenatide (twice-daily and once-weekly formulations) and liraglutide once daily.
Lixisenatide (AVE0010) is a new selective once-daily GLP-1 receptor agonist in development for the treatment of type 2 diabetes mellitus (6–8). It is a 44-amino acid peptide that is amidated at the C-terminal end and shares some structural elements with exendin-4 (the main difference being the addition of 6 lysine residues at the C terminus) (9). Lixisenatide is highly selective for the GLP-1 receptor and exerts about fourfold higher affinity for the GLP-1 receptor than native human GLP-1 (9). The preclinical pharmacological profile of lixisenatide suggests that stimulation of insulin secretion by lixisenatide is strictly glucose dependent. In animal models, lixisenatide enhances insulin biosynthesis and stimulation of β-cell proliferation and delays gastric emptying and reduces food intake (9). In human islets, lixisenatide prevents lipotoxic islet insulin depletion and preserves insulin production, storage, and pancreatic β-cell function (9). Lixisenatide undergoes renal metabolism, but mild or moderate renal impairment does not appear to influence its pharmacokinetics or tolerability (10).
In a 13-week, randomized, double-blind, placebo-controlled, parallel-group, phase II dose-ranging study, lixisenatide administered at doses of 5, 10, 20, or 30 μg once daily or twice daily in patients with type 2 diabetes inadequately controlled with metformin significantly improved HbA1c compared with placebo (8). Dose-dependent improvements were also observed for fasting plasma glucose (FPG) and postprandial plasma glucose (PPG) associated with the morning meal and average self-monitored seven-point blood glucose levels (7). The dose of 20 μg administered once daily was found to provide the optimal balance of efficacy and tolerability (8).
Accordingly, in this Phase III study, we assessed the safety and efficacy of 20 μg lixisenatide once daily in a 12-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group monotherapy trial in patients with type 2 diabetes not currently receiving glucose-lowering therapy.
Study participants
The study population comprised male and female patients aged 20–85 years with type 2 diabetes mellitus not currently receiving glucose-lowering therapy and with glycated hemoglobin (HbA1c) ≥7.0% and ≤10.0%. The main exclusion criteria were as follows: treatment with a glucose-lowering pharmacological agent within the previous 3 months; FPG at screening >250 mg/dL (13.9 mmol/L); amylase and/or lipase >3 times the upper limit of the normal (ULN) laboratory range; clinically relevant history of gastrointestinal disease with prolonged nausea and vomiting during the previous 6 months, chronic pancreatitis, or stomach/gastric surgery; history of myocardial infarction, stroke, or heart failure requiring hospitalization within the previous 6 months; hepatic disease, end-stage renal disease, and/or dialysis at screening.
The study was approved by the institutional review boards or ethics committees and was conducted in accordance with the Declaration of Helsinki and Good Clinical Practice guidelines. All patients gave written informed consent to participate in the study.
This 12-week, multinational, randomized, parallel-group, placebo-controlled study was conducted at 61 centers in 12 countries (Belgium, India, Israel, Japan, South Korea, Mexico, Poland, Romania, Russian Federation, Tunisia, Ukraine, and United States) between 2008 and 2009. The study drug was double-blind regarding active treatment or placebo and open-label regarding the treatment volume and dose increase regimen.
After a 2-week screening phase, eligible patients entered into a 1-week, single-blind, placebo run-in period. Eligible patients were then randomized to receive one of four treatment regimens in a 1:1:1:1 ratio for 12 weeks: 1) lixisenatide 2-step dose increase (10 μg for 1 week, 15 μg for 1 week, and then 20 μg), 2) lixisenatide 1-step dose increase (10 μg for 2 weeks and then 20 μg), 3) placebo 2-step dose increase, and 4) placebo 1-step dose increase. This was followed by a 3-day, posttreatment follow-up period. All treatments were administered once daily within 1 h before breakfast. Routine fasting self-measured plasma glucose and central laboratory alerts on FPG were set up to ensure that glycemic parameters remained under predefined thresholds values (defined depending on study period as: FPG >270 mg/dL [15.0 mmol/L] from baseline visit [day 1] to visit 8, week 8; FPG >240 mg/dL [13.3 mmol/L] from visit 8, week 8 to visit 9, week 12). Rescue medication was introduced in subjects with FPG above those thresholds values, if no reasonable explanation existed for insufficient glucose control, or if appropriate action failed to decrease FPG. Metformin was recommended as first-line rescue medication.
Randomization of subjects, allocation of medication, and management of drug supplies was performed using an Interactive Voice Response System. Patients were stratified by screening values of HbA1c (<8%, ≥8%) and BMI (<30 kg/m2, ≥30 kg/m2). All patients received diet and lifestyle counseling according to the American Diabetes Association guidelines (11).
Study assessments
The primary efficacy end point was change in HbA1c from baseline to study end for the intent-to-treat population. All clinical laboratory assessments, including HbA1c, were measured at a National Glycohemoglobin Standardization Program Level 1 certified central laboratory (Covance), using a high performance liquid chromatography method.
The secondary efficacy measures included the percentage of patients achieving an HbA1c <7.0% or ≤6.5%, change in FPG, and change in body weight. The secondary efficacy measures of 2-h PPG and 2-h glucose excursion (defined as 2-h PPG minus plasma glucose 30 min before the breakfast meal test before study drug administration) were assessed for a subgroup of patients at selected sites during a standardized meal test. For logistic reasons, the 2-h PPG after standardized meal challenge test was only assessed in a subgroup of all the patients in selected sites (∼50% of the randomized patients). In a selected country, all sites and all patients should undergo the meal test. The countries for the meal test were selected according to the following criteria: the anticipated number of patients to be enrolled (based on feasibility); balanced ethnicity at the end, as far as possible; and easy implementation of the meal test substudy (i.e., fast approval, easy import license for the meal test drink (Ensure Plus).
The meal test consisted of a 600 kcal liquid meal (400 mL of Ensure Plus; Abbott Nutrition, Columbus, OH) composed of 53.8% carbohydrate, 16.7% protein, and 29.5% fat and was to be consumed within a 10-min period, 30 min after drug administration at week −1 and week 12. Blood was sampled at 3 time points: 1) 30 min before the meal test (before study drug administration), 2) just before consumption at the start of the meal test (0 min), and 3) 120 min after the start of the meal test. Antilixisenatide antibody levels were measured. Antilixisenatide antibody status and concentration were measured by Biacore. It is a commercial system that is validated and complies with the current regulatory standards, based on Surface Plasmon Resonance using Biacore technology.
Safety and tolerability were assessed by physical examination, blood pressure, heart rate, 12-lead electrocardiogram, standard laboratory measurements, antilixisenatide antibodies, and adverse events reporting (including, in particular, symptomatic and severe symptomatic hypoglycemia, local intolerability at injection site, allergic or allergic-like reactions, suspected pancreatitis, and major cardiovascular events). Symptomatic hypoglycemia was defined as symptoms consistent with hypoglycemia, with accompanying blood glucose <3.3 mmol/L (60 mg/dL) and/or prompt recovery with carbohydrate. Severe symptomatic hypoglycemia was defined as symptomatic hypoglycemia in which the patient required the assistance of another person and which was associated either with a plasma glucose level <36 mg/dL (2.0 mmol/L) or, if no plasma glucose measurement was available, with prompt recovery with carbohydrate.
The safety population comprised all randomized patients exposed to at least one dose of investigational drug.
The two placebo groups were combined in all analyses. Sample sizes of 120 patients in each lixisenatide treatment group and the combined placebo group were calculated to provide a statistical power of 90% to detect a 0.5% difference in HbA1c between active treatment and placebo assuming a standard deviation of 1.2%. Statistical significance was assumed at the 5% level. All statistical computations were performed using SAS, version 8.2 or higher.
Analyses of the primary efficacy variable (changes in HbA1c from baseline to end point) were performed using an ANCOVA model, with treatment group, screening strata for HbA1c and BMI, and country as fixed factors and baseline HbA1c as a covariate. The same method was used for analysis of secondary efficacy parameters. The Last Observation Carry Forward procedure was used to handle missing assessments, early discontinuation, or introduction of rescue therapy during the double-blind treatment period. Least squares (LS) means were calculated from the model to estimate treatment effect size. Comparisons between each lixisenatide group and placebo were based on treatment differences using the LS means. A step-down testing procedure was applied. The lixisenatide 2-step dose increase arm was first compared with the combined placebo group (primary objective); if the test was statistically significant, then the lixisenatide 1-step dose increase arm was compared with the combined placebo group (secondary objective). The percentage of patients achieving HbA1c <7.0% or ≤6.5% and the percentage of patients requiring rescue therapy were analyzed using a Cochran-Mantel-Haenszel test stratified according to screening HbA1c and screening BMI.
Unless otherwise indicated, all efficacy data were analyzed in the intent-to-treat population, comprising all randomized patients who received at least one dose of double-blind investigational drug (lixisenatide or placebo) and had both a baseline assessment and at least one postbaseline assessment of any primary or secondary efficacy variable. Only two patients were excluded from the efficacy analyses because of lack of postbaseline efficacy data. Results are presented as mean ± SEM, unless otherwise specified.
Demographic and baseline characteristics
A total of 361 patients were randomized and treated from 795 patients screened. The main reason for screening failure was an HbA1c value out of the defined protocol range at the screening visit. The demographic and baseline characteristics of the combined placebo group and the two lixisenatide treatment groups were well matched, and there were no clinically relevant differences between groups (see Table 1 and Supplementary Fig. 1).
Patient disposition, demographics, and baseline characteristics (safety population)
The majority of patients (n = 331 [91.7%]) completed the 12-week double-blind treatment period. Overall, 30 patients discontinued treatment prematurely, including 10 (8.3%) in the lixisenatide 2-step dose increase arm, 11 (9.2%) in the lixisenatide 1-step dose increase arm, and 9 (7.4%) in the combined placebo group. A total of eight lixisenatide-treated patients (3.3%) discontinued as a result of an adverse event and none as a result of lack of efficacy (see Supplementary Fig. 1). Out of the 361 patients in the safety population, 335 (92.8%) were exposed to 57 days or more of study drug (mean 81.3 days for placebo, 81.2 days for lixisenatide 2-step, and 81.8 days for lixisenatide 1-step), 349 (96.7%) reached the target dose of 20 μg at the end of dose increase period (98.4% placebo, 95.0% lixisenatide 2-step, 96.6% lixisenatide 1-step), and 335 (92.8%) were receiving 20 μg at the end of double-blind treatment (99.2% placebo, 90.8% lixisenatide 2-step, 88.2% lixisenatide 1-step). Only six patients required rescue medication during the study (3 [2.5%] in the placebo group, 2 [1.7%] in the lixisenatide 2-step group, and 1 [0.8%] in the lixisenatide 1-step group).
Efficacy.
Lixisenatide once daily significantly decreased HbA1c from baseline to week 12 (Fig. 1A). The LS mean changes at end point in HbA1c were −0.19, −0.73, and −0.85% from a baseline of 8.07, 7.97, and 8.06% for the combined placebo, 2-step, and 1-step dose increase groups, respectively. LS mean differences versus placebo were −0.54% for the 2-step and −0.66% for the 1-step dose increase arm (both P values <0.0001). Out of the lixisenatide-treated patients, 56% in the 2-step dose increase group and 60% in the 1-step dose increase group developed antilixisenatide antibodies after 12 weeks of lixisenatide treatment. HbA1c reduction was similar in antilixisenatide antibody-positive and -negative patients.
Changes in glycated hemoglobin (HbA1c) levels after 12 weeks' treatment with lixisenatide (according to dose increase regimen) or placebo. A: Mean change (±SEM) in HbA1c over time. B: Percentage of patients achieving HbA1c goals <7.0% and ≤6.5%. LOCF, Last Observation Carry Forward.
The goal of HbA1c <7.0% was achieved by significantly more patients in both the lixisenatide 2-step (52%) and 1-step (47%) groups compared with placebo (27%; both P values <0.01) (Fig. 1B). A significantly greater response rate was also achieved for the goal of HbA1c ≤6.5% (32 and 25 vs. 13%; both P values <0.01) (Fig. 1B).
In the 169 patients who participated in the standardized meal test and had both baseline and end point evaluation, the treatment with lixisenatide significantly improved postprandial glycemic control as shown by the results of the 2-h postprandial plasma glucose assessment (both P values <0.0001) (Fig. 2). Treatment with lixisenatide significantly decreased the 2-h glucose excursion from baseline to week 12 compared with the combined placebo group (LS mean difference vs. placebo of −3.1 mmol/L; 95% CI [−4.30 to −1.90] for the lixisenatide 2-step and −3.7 mmol/L; 95% CI [−4.85 to −2.53] for the lixisenatide 1-step dose increase arm) (Fig. 2).
Changes in postbreakfast glucose parameters from baseline after 12-weeks' treatment with lixisenatide (according to dose increase regimen) or placebo. LS mean change in mean (±SEM) 2-h PPG levels is shown. LS mean change in 2-h glucose excursion is also shown. Data are from patients undergoing a standardized breakfast meal test at selected sites. Glucose excursion = 2-h PPG, plasma glucose 30 min before the meal test before study drug administration. Mean ± SD baseline values for 2-h PPG: 13.99 ± 4.78 mmol/L (placebo), 14.67 ± 3.78 mmol/L (lixisenatide 2-step), 14.55 ± 3.36 mmol/L (lixisenatide 1-step). Mean ± SD baseline values for glucose excursion: 4.72 ± 3.65 mmol/L (placebo), 5.45 ± 3.02 mmol/L (lixisenatide 2-step), 5.25 ± 2.89 mmol/L (lixisenatide 1-step). To convert mmol/L to mg/dL, divide by 0.0555.
Treatment with lixisenatide also decreased FPG compared with the combined placebo group: LS mean difference versus placebo: −0.9 mmol/L for the 2-step (P value <0.001) and −1.1 mmol/L for the lixisenatide 1-step dose increase arm (P value <0.0001) (see Supplementary Fig. 2).
Body weight decreased by ∼2 kg in all groups, with no significant differences between lixisenatide and placebo.
Safety and tolerability
Approximately 50% of patients experienced a treatment-emergent adverse event (TEAE), with a slightly higher rate in the lixisenatide groups than the placebo group (Table 2). There was only one serious TEAE among lixisenatide-treated patients (a case of goitre in the 2-step group) compared with five serious events in the placebo group.
Number (%) of patients with TEAEs occurring in ≥5% (preferred term) in any one group and symptomatic hypoglycemia in the safety population
The most common TEAEs were gastrointestinal in nature, with nausea being the most frequent (Table 2). Nausea was reported more frequently in patients treated with lixisenatide compared with patients treated with placebo (24.2, 20.2, and 4.1% of patients in the lixisenatide 2-step and 1-step dose increase and combined placebo group, respectively), more frequently during the first 3 weeks of treatment with a reduced occurrence from week 7 and up to the end of treatment. Most of the events were mild to moderate in intensity and resolved without the need to administer corrective treatment.
Vomiting was also reported more frequently in the lixisenatide-treated group (Table 2). Most of the events occurred during the first 3 weeks of treatment (with a reduced occurrence from week 6 and up to the end of treatment), were mild to moderate in intensity, and resolved without the need to administer corrective treatment.
One placebo-treated patient and eight lixisenatide-treated patients (5 [4.2%] 2-step, 3 [2.5%] 1-step) discontinued treatment because of a TEAE. Gastrointestinal disorders were at least partly responsible for the discontinuations in all eight lixisenatide-treated patients (additional reasons were one case of decreased appetite and one case of hypertension).
A total of six cases (3 [2.5%] lixisenatide 2-step dose increase, 1 [0.8%] lixisenatide 1-step dose increase, and 2 [1.6%] placebo patients) of symptomatic hypoglycemia fulfilling the protocol definition were observed, and none of them was severe or led to treatment discontinuation.
There were no reports of suspected pancreatitis during the study, and no instances of lipase or amylase elevation ≥3×ULN.
Injection site reactions were reported by 11 (4.6%) patients, all in the lixisenatide-treated group. None of the events was serious or severe in intensity or led to treatment discontinuation.
Two patients in the lixisenatide 1-step dose increase arm had allergic events considered as possibly related to therapy (urticaria in one case and angioedema in the other case). None of the events was serious. The patient with urticaria recovered with symptomatic treatment and was able to complete the study without recurrence of the event. For the patient with angioedema, the study treatment was discontinued because of vomiting and abdominal pain. No significant differences in adverse events were observed between the antibody-positive and antibody-negative patient population.
In the current study involving patients with type 2 diabetes not receiving glucose-lowering therapy, lixisenatide monotherapy administered once daily for 12 weeks and titrated using either 1 step or 2 steps up to the maintenance dose of 20 μg once daily provided significant improvements in HbA1c compared with placebo and allowed more patients to achieve HbA1c goals. The magnitude of improvement in HbA1c (placebo-subtracted change of −0.54 and −0.66% from a baseline of 8.0% ± 0.9 and 8.1% ± 0.9 for the 2-step and 1-step dose increase groups, respectively) is consistent with that seen with exenatide twice daily when administered as monotherapy in treatment-naïve patients (placebo-subtracted change of −0.5% with 5 μg and −0.7% with 10 μg twice-daily exenatide from a baseline of 7.8%) (12). No other placebo-controlled studies are available for GLP-1 receptor agonist monotherapy in a similar patient population. The only available study with liraglutide monotherapy used the active comparator glimepiride, and many patients had been treated previously with oral agent monotherapy (13).
In the current study, there was a pronounced effect of lixisenatide on PPG associated with the morning meal, with statistically significant and clinically meaningful improvement of both 2-h PPG (−4.5, −5.5, and −0.7 mmol/L for the 2-step and 1-step dose increase and placebo groups, respectively) and blood glucose excursions (−3.8, −4.4, and −0.7 mmol/L for the 2-step and 1-step dose increase and placebo groups, respectively) measured during a standardized meal test. This represents a 75% reduction in the postprandial glucose excursion. These results are consistent with those of previous studies of lixisenatide (6–8) and greater than those observed for monotherapy with liraglutide 1.2 mg and 1.8 mg (1.7 and 2.1 mmol/L decreases in PPG averaged across all meals, respectively), although breakfast PPG was not reported specifically in that study (13). The importance of targeting PPG is now recognized by international organizations and the International Diabetes Federation recommends that patients with diabetes manage their HbA1c levels to <6.5% by addressing both FPG and PPG, with 2-h PPG level targets of <7.8 mmol/L (140 mg/dL) (14).
Lixisenatide monotherapy also provided improvements in FPG (−0.9 mmol/L for the 2-step and −1.1 mmol/L for the lixisenatide 1-step dose increase arms [both P values <0.001]). This is comparable with changes observed with liraglutide monotherapy (1.2 mg = −0.8 and 1.8 mg = −1.4 mmol/L) (13). In this study, lixisenatide provided a mean weight loss of ∼2 kg, which is comparable with what was reported after 12 weeks of treatment with other GLP-1 receptor agonists when administered as monotherapy (12,13).
The glucose-lowering efficacy of lixisenatide can be considered independently of any potential impact because of weight loss since, in the current study, the weight loss observed was not different to that seen with placebo. The patients included in the study had a short duration of diabetes and were not receiving any glucose-lowering therapy and were therefore probably the most sensitive and compliant to dietary interventions, which can explain the weight loss observed with the placebo in this 12-week study. This weight change in the placebo group is compatible with that seen in other studies where lifestyle changes occur in the placebo group, but are usually short lived (15,16).
We found that lixisenatide was well tolerated, with no difference between the 2-step and 1-step dose increase regimens. As expected, the most frequent adverse events were gastrointestinal in nature: mainly nausea, with low rates of vomiting. Most of these events were transient, mild to moderate in intensity, and resolved spontaneously. Only very few led to treatment discontinuation. The nausea frequency (22% for the combined lixisenatide groups) is consistent with the frequency observed in the lixisenatide dose–ranging study (25.5% with 20 μg once-daily dose) and in studies conducted with other GLP-1 receptor agonists when used in monotherapy (13–29%) (12,13). Rates of symptomatic hypoglycemia associated with lixisenatide in the current study were low (with no severe events) and similar to placebo. Although this study is only of 12 weeks' duration, additional Phase III studies have had a main 24-week treatment period and the majority has also included long-term extension periods of at least another year to assess long-term safety and tolerability. Antibody concentration was very low in the majority of patients, and available data suggest that HbA1c reduction and overall safety profile are similar in antilixisenatide antibody-positive and -negative patients (8). The potential influence of antibodies in the longer term will be addressed in publications of longer-term trials from the GetGoal program.
The current study shows that lixisenatide once daily is effective and well tolerated when used as monotherapy in treatment-naïve patients. The impact of lixisenatide on hyperglycemia around the morning meal may also be advantageous, since this component of glycemia appears to be relatively resistant to oral therapies (17). Recent data in metformin-treated patients also suggest that lixisenatide once daily is noninferior to exenatide twice daily in terms of HbA1c reduction, but has the advantages of less hypoglycemia and fewer gastrointestinal adverse events (18).
In conclusion, the results from this first completed study in the Phase III clinical trials program for lixisenatide have demonstrated that lixisenatide monotherapy administered once daily provides significant improvements in glycemic control with a pronounced postprandial effect. In addition, lixisenatide was safe and well tolerated, and there was no relevant difference in the safety and tolerability of the 1-step and 2-step dose increase regimens. The results support a role for once-daily lixisenatide monotherapy using a 1-step dose increase regimen in patients not controlled on lifestyle interventions and highlight the potential of lixisenatide for further development as a glucose-lowering compound to treat patients with type 2 diabetes.
The study was funded by sanofi-aventis, the manufacturer of lixisenatide. The investigators and representatives from sanofi-aventis were responsible for the study design, protocol, statistical analysis plans, analysis, and reporting of the results. Final responsibility for the decision to submit the manuscript for publication was made jointly by all authors.
V.A.F. received research support from Novo Nordisk, sanofi-aventis, Eli Lilly, Daiichi-Sankyo, Pamlabs, Reata, and Halozyme and honoraria from GlaxoSmithKline, Takeda, Novo Nordisk, sanofi-aventis, Eli Lilly, Daiichi-Sankyo, Pamlabs, Xoma, and AstraZeneca for consulting and lectures. R.A.-R. received grant/research support from GlaxoSmithKline, AstraZeneca, Boehringer Ingelheim, sanofi-aventis, Public Health Research Institute, and Roche and honoraria from Pfizer, sanofi-aventis, AstraZeneca, and Merck Sharp & Dohme for consulting and advisory board attendance. G.B. and P.M. are employees of sanofi-aventis. J.E.G. has sat on advisory boards/provided consultancy for AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Johnson & Johnson, MannKind Corporation, Merck, and sanofi-aventis and is on the Speakers' Bureau for Bristol-Myers Squibb/AstraZeneca, Boehringer Ingelheim, Merck, and sanofi-aventis and on the Data and Safety Monitoring Board for sanofi-aventis.
No other potential conflicts of interest relevant to this article were reported.
V.A.F. and J.E.G. researched data, reviewed and edited the manuscript, and contributed to the discussion of the data. R.A.-R. and D.R. reviewed and edited the manuscript and contributed to the discussion of the data. G.B. researched data, wrote the manuscript, reviewed and edited the manuscript, and contributed to the discussion of the data. P.M. researched data. V.A.F. is the guarantor of this work and, as such, had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.
Parts of this study were presented in poster form at the 46th Annual Meeting of the European Association for the Study of Diabetes, Stockholm, Sweden, 20–24 September 2010.
The authors thank all of the investigators, coordinators, and patients who took part in this study. Editorial assistance was provided by Susan Crawford, Absolute Healthcare Communication and funded by sanofi-aventis.
Clinical trial reg. no. NCT00688701, clinicaltrials.gov.
This article contains Supplementary Data online at http://care.diabetesjournals.org/lookup/suppl/doi:10.2337/dc11-1935/-/DC1.
Nathan DM,
Buse JB,
Davidson MB,
American Diabetes Association,
European Association for Study of Diabetes
. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009;32:193–203pmid:18945920
Rodbard HW, Jellinger PS, Davidson JA, et al. Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control. Endocr Pract 2009;15:540–559
Madsbad S
. Exenatide and liraglutide: different approaches to develop GLP-1 receptor agonists (incretin mimetics)—preclinical and clinical results. Best Pract Res Clin Endocrinol Metab 2009;23:463–477pmid:19748064
Russell-Jones D
. The safety and tolerability of GLP-1 receptor agonists in the treatment of type-2 diabetes. Int J Clin Pract 2010;64:1402–1414pmid:20716148
Buteau J
. GLP-1 receptor signaling: effects on pancreatic beta-cell proliferation and survival. Diabetes Metab 2008;34(Suppl. 2):S73–S77pmid:18640589
Distiller LA,
Ruus P,
ACT6011 Study Group
. Pharmacokinetics and pharmacodynamics of a new GLP-1 agonist AVE0010 in type 2 diabetes patients (Abstract). Diabetes 2008;57(Suppl. 1):A154–A155
Ratner RE,
Rosenstock J,
Boka G,
Silvestre L
. Post-meal pharmacodynamic profile of AVE0010, a once-daily GLP-1 receptor agonist, in patients with type 2 diabetes inadequately controlled on metformin (Abstract). Diabetologia 2009;52(Suppl. 1):S60
DRI6012 Study Investigators
. Dose-dependent effects of the once-daily GLP-1 receptor agonist lixisenatide in patients with type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled trial. Diabet Med 2010;27:1024–1032pmid:20722676
Werner U,
Haschke G,
Herling AW,
Kramer W
. Pharmacological profile of lixisenatide: A new GLP-1 receptor agonist for the treatment of type 2 diabetes. Regul Pept 2010;164:58–64pmid:20570597
Liu Y-H,
Ruus P
. Pharmacokinetics and safety of the GLP-1 agonist AVE0010 in patients with renal impairment (Abstract). Diabetes 2009;59(Suppl. 1):A149–A150
. Standards of medical care in diabetes—2008. Diabetes Care 2008;31(Suppl. 1):S12–S54pmid:18165335
Moretto TJ,
Milton DR,
Ridge TD,
. Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther 2008;30:1448–1460pmid:18803987
Garber A,
Ratner R,
LEAD-3 (Mono) Study Group
. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet 2009;373:473–481pmid:18819705
Ceriello A,
Colagiuri S
. International Diabetes Federation guideline for management of postmeal glucose: a review of recommendations. Diabet Med 2008;25:1151–1156pmid:19046192
Norris SL, Zhang X, Avenell A, Gregg E, Schmid CH. Lau J. Pharmacotherapy for weight loss in adults with type 2 diabetes mellitus. Cochrane Database Syst Rev 2005;1:CD004096
Norris SL, Zhang X, Avenell A, et al. Long-term non-pharmacological weight loss interventions for adults with type 2 diabetes mellitus. Cochrane Database Syst Rev 2005;2:CD004095
Monnier L,
Colette C,
Rabasa-Lhoret R,
. Morning hyperglycemic excursions: a constant failure in the metabolic control of non-insulin-using patients with type 2 diabetes. Diabetes Care 2002;25:737–741pmid:11919134
Raccah D,
Koranyi L,
. Efficacy and safety of lixisenatide once-daily vs. exenatide twice-daily in type 2 DM inadequately controlled on metformin (GetGoal-X) (Abstract). Diabetes 2011;60(Suppl. 1A):LB10
You are going to email the following Efficacy and Safety of the Once-Daily GLP-1 Receptor Agonist Lixisenatide in Monotherapy
Vivian A. Fonseca, Ricardo Alvarado-Ruiz, Denis Raccah, Gabor Boka, Patrick Miossec, John E. Gerich, on behalf of the EFC6018 GetGoal-Mono Study Investigators
Diabetes Care Jun 2012, 35 (6) 1225-1231; DOI: 10.2337/dc11-1935
Insulin Resistance Is Associated With Enhanced Brain Glucose Uptake During Euglycemic Hyperinsulinemia: A Large-Scale PET Cohort
Not Only Diabetes but Also Prediabetes Leads to Functional Decline and Disability in Older Adults
Changes in Plant-Based Diet Indices and Subsequent Risk of Type 2 Diabetes in Women and Men: Three U.S. Prospective Cohorts
Show more Original Research
Clinical Care/Education/Nutrition/Psychosocial Research
Emotional Regulation and Diabetes Distress in Adults With Type 1 and Type 2 Diabetes
Long-term Follow-up of Glycemic and Neurological Outcomes in an International Series of Patients With Sulfonylurea-Treated ABCC8 Permanent Neonatal Diabetes
The Impact of Physical Activity on the Prevention of Type 2 Diabetes: Evidence and Lessons Learned From the Diabetes Prevention Program, a Long-Standing Clinical Trial Incorporating Subjective and Objective Activity Measures
Show more Clinical Care/Education/Nutrition/Psychosocial Research


text:
Unveiled for the first time in more than half a century
Last exhibited in 1962, Francis Bacon's Head with Raised Arm (1955) will be offered in Christie's Post-War and Contemporary Art Evening Auction, a highlight of London's Frieze Week auctions in October
According to writer, art historian and curator Michael Peppiatt, 'Bacon's Popes are not only the centrepiece of all his paintings in the 1950s, but a centrepiece of the whole of 20th-century art.'
Last exhibited in 1962 at the Galleria Civica d'Arte Moderna, Turin, Head with Raised Arm (1955) was acquired by the present owners in the following year, and has remained hidden from public view ever since. The work's location was listed as 'unknown' in the most recent version of Francis Bacon's catalogue raisonné, edited by Martin Harrison and published last year.
'This is a landmark moment,' states Francis Outred, Chairman and Head of Post-War and Contemporary Art at Christie's, 'marking the reappearance of a major Bacon portrait after more than 50 years.'
Francis Bacon (1909-1992), Head with Raised Arm, 1955. 24 x 20 in (61 x 50.7 cm). Estimate: £7,000,000-10,000,000. This lot is offered in Post-War and Contemporary Art Evening Auction on 6 October 2017 at Christie's in London © The Estate of Francis Bacon. All rights reserved / DACS, London / ARS, New York 2017
Filled with tension and quiet introspection, the work belongs to a group of nine surviving paintings depicting the then-incumbent pope, Pius XII, who would reign for a further three years until his death in 1958. Four are held in museum collections, and an additional work is on permanent loan.
'Bacon's Head with Raised Arm poses the question that would haunt Bacon for the duration of his career: how to paint the human figure in the age of photography,' continues Outred. 'The camera's ability to cast fiction as truth resonated with the fundamental tension that Bacon identified in religious and political figureheads: a conflict between public image and innate animal instinct.'
Evoking the works of Eadwaerd Muybridge, as well as anticipating Gerhard Richter's blurred photo-paintings of the following decade, Head with Raised Arm speaks directly to this theme. Pius was the only living Pope that Bacon would ever try to capture, and by hinting at the transience of a figure immortalised through the camera lens, Bacon lifts the veil on his humanity.
By hinting at the transience of a figure immortalised through the camera lens, Bacon lifts the veil on his humanity
The Pope's face and arm flicker like moving images caught on camera, animated by a veil of rapid hairline striations. With its vertical combing with a fine brush over layers of colour, the work demonstrates Bacon's dialogue with photography in his bid to capture what he termed 'the trail of the human presence'.
Rare for its closely-cropped depiction of the pontiff's head and shoulders, the present work confronts its subject on a piercing, intimate scale. It is one of only two Popes executed in Bacon's jewel-like 24-by-20-inch format, aligning it with his first small portrait triptych of 1953.
Pius had been elected to the papacy in 1939 and his reign spanned the Second World War, famously drawing accusations of silence in the face of atrocity. As the Church and media sought to uphold his infallibility, the artist cast him as a fragile, flawed being, tortured by the weight of his grand station.
'The Pope is put in a unique position by being the Pope, like in certain great tragedies' — Francis Bacon
Pursued over nearly two decades, and numbering more than 50 canvases, Bacon's Papal portraits are widely regarded as his finest achievements. These works were his first and most significant existential enquiries, and stand today among the foremost images of the 20th century.
'It's true, of course, the Pope is unique', Bacon explained. 'He's put in a unique position by being the Pope, and therefore, like in certain great tragedies, he's as though raised onto a dais on which the grandeur of this image can be displayed to the world.'
During the 1950s, Head with Raised Arm was owned by the pioneering Bacon collectors James and Brenda Bomford, who acquired the work from the dealer Kenneth John Hewett. The Bomfords purchased a number of significant works by Bacon during this period, many of which are now held in important museum collections. As well as the landmark painting Head VI, 1949 (Arts Council Collection, Southbank), they owned five portraits of Pius, including Pope II, 1951 (Kunsthalle Mannheim), Figure Sitting, 1955 (Stedelijk Museum voor Actuele Kunst, Ghent), Study for a Head, 1955, and Study for Portrait II, as well as the present work.
Head with Raised Arm will be on view from 8 September at Christie's Rockefeller Center, New York; from 18 September at Christie's Hong Kong; and from 30 September 2017 at Christie's King Street.
Left: Francis Bacon, Head with Raised Arm, 1955. Estimate: £7-10 million. This work is offered in the Post-War and Contemporary Art Evening Auction on 6 October 2017 at Christie's London. Right: Francis Bacon, London, early 1970s (from the artist's studio) (detail). Photo: © Henri Cartier-Bresson / Magnum Photos. Source clipping: © The Estate of Francis Bacon. All rights reserved. DACS 2017
Dedicated catalogue
Francis Bacon, Head with Raised Arm, 1955
Icons of the spirit and the flesh — Francis Bacon's two greatest obsessions
Post-War and Contemporary Art Evening Auction
Up Close An Evening Auction
Masterpieces of Design & Photography
Thinking Italian
Post-War and Contemporary Art Day Auction
Unseen in public for almost 45 years, the deeply poignant Study of Red Pope, 1962, 2nd version is to be offered at Christie's London in October
Howard Hodgkin: 'One of the very greatest painters of the last 50 years'
Art critic and author Andrew Graham-Dixon takes a closer look at The Green Chateau and Goodbye to the Bay of Naples
'My women are beautiful in their individuality'
Ahead of the auction of two seminal early works by Jenny Saville in London, we take a look at how the British artist's work has evolved
Boom for Real: Basquiat comes to London
A sneak preview of the UK's first major Basquiat retrospective, with Barbican curator Dieter Buchhart
'To me, it was always visceral'
Irving Stenn Jr reveals how he assembled one of the top collections of post-war and contemporary works on paper in the United States
Masterworks from the Collection of Antoni Tàpies
Offered in October 2017 and February 2018, and featuring passionately cherished works by Alberto Giacometti, Joan Miró, Pablo Picasso and Mark Rothko
'Sculpture is a catalyst for a re-engagement with the elements and matter'
Sir Antony Gormley discusses the inspiration for his landmark 1989 sculpture A Case for an Angel I
Special Publication: Francis Bacon, Head with Raised Arm
Last exhibited in 1962, Francis Bacon's Head with Raised Arm will be offered at Christie's London during Frieze Week


Damn. In a terrifying accident in Utah, a FrontRunner train crashed into a FedEx truck and basically shredded its trailer into pieces, sending boxes flying everywhere. Thankfully (and impressively), there were no serious injuries in the crash, as it seemed the train busted through the softest part of the FedEx truck.


Uriah's mom, Kasidy, and I went to high school together, so when she reached out about having his six month pictures taken, I was thrilled. I hadn't seen her since she graduated a year before me, so it was great catching up and meeting her husband and sweet baby. It's crazy how fast time flies, but I swear she hasn't changed a bit in the past what… seven years (?!!!) since I last saw her. She was just as sweet and fun as I remembered, and all the memories from running cross country together came flooding back. For months we spent almost every afternoon sweating it out together running around Bonham, and those aren't memories you easily forget. 😉 I actually found this picture of us after our district meet, and wow- we were babies!
I had such an amazing time traipsing around my in-law's property for our session (and maybe getting a little lost at one point…). It was a hot and humid morning, but totally worth it for some sweet baby snuggles.
Thank you Kasidy and Dylan for letting me capture this exciting moment in time for y'all! I look forward to seeing how you continue to model the Lord's love, grace and patience to your baby boy.


We are also pleased to give rating solutions to qualify new homes for the POWER CELEBRITY tag. POWER CELEBRITY qualified new houses are significantly a lot more energy reliable compared to homes developed to the minimum code requirements. Even in states with even more extensive energy codes, the U.S. EPA guarantees that ENERGY CELEBRITY continues to be the symbol for genuinely energy-efficient performance. These homes benefit companies, consumers, and also the environment.
Be the first to read what the experts are saying about selling my property Germantown.
So let's wrap-up. When making an offer to acquire a residence, you have to recognize that it's called an "asking rate" for a factor. It's exactly what the seller is asking to obtain. But it may not reflect real market price of the home in the current realty market. So you (and also your property representative) should do some homework. Beginning by making as well as watching the residential or commercial property note of exactly what it has to supply. Then bring up some equivalent sales for the area. Take into consideration the "target home" against the compensations, factoring in the unique features it might supply. This is exactly how you think of a sensible deal quantity.
Oops! We don't. acknowledge the web browser you're presently using. Try inspecting the internet browser's help food selection, or searching the Internet for guidelines to switch on HTML5 Geolocation for your internet browser. You can also search near a city, address, or area rather.
There's never ever been a better time to buy #Tennessee:t# confiscated homes offer for sale. Foreclosed homes in #Tennessee:t# are readily available for exceptionally inexpensive costs, often as much as 50%. Our team could aid anybody find #Tennessee:t# repossession homes offer for sale from Germantown to Germantown! Our #Tennessee:t# foreclosure listings data source allows you find terrific foreclosed homes in #Tennessee:t# for spending today, so you can invest more time checking out which #Tennessee:t# foreclosures to purchase.
Choosing A Real Estate Agent To Offer Your house Meet representatives on-the-job: As opposed to having a sit-down meeting at the office or your home, learn the next open-house organized by your chosen real estate agent and go attend it, even if you are not going there for there the property. If the agent is ideal for you and witness your possible representative live in activity, use this a secret store to establish!
How you can Make An Offer On A Residence Set monetary limits before you start bidding, and established rigorous rules for when you'll leave. Lastly, take into consideration affixing a cover letter to your offers that briefly defines you and also exactly how you plan on taking care of your house, residential or commercial property, and so on. Sometimes owners are a lot more curious about somebody that comprehends the uniqueness of your house or who assures to take good treatment of it.
Ciiity City is one of the hottest real estate markets in the country if you haven't seen the fad by now. A renewed economy has assisted the city run and take the recovery with it. Possibly a lot more significantly, however, are the aggressive steps to building a better real estate field the brand-new mayor has taken. Bill TN Blasio has actually launched a huge affordable real estate construction campaign to add to the growth of Germantown City. These elements, and also numerous others, have advertised healthy development in the 5 boroughs.
Relying on the type of insolvency you file, that mark will remain on your credit record for as much as 10 years. AChapter 13 personal bankruptcy remains on your document for 7 years; a Chapter 7 or Chapter 11 bankruptcy for Ten Years.
World Property Directory site I speak from experience on this topic. When I got my initial house in #Tennessee:t#, it was a total seller's market. We made the error of attempting to work out a few times, and also we had numerous houses slide throughout our fingers. We promptly readjusted our approach as well as made full-price deals, as long as the market sustained the asking rate. We were still up against multiple offers, however eventually we got ours accepted. We merely had to realize the negotiating power re#Tennessee:t#d in the vendor's favor.
What To Offer On A Home Available For Sale Allowing your feelings get the best of you throughout a very difficult time usually does not end up well. "It could be extremely discouraging to come to be affixed to the possibility of owning a details building, just to lose in a bidding process battle," says Andrew Sobel, Vice President of Sobel Real Estate. Yet that doesn't mean you cannot have all your ducks in order as you enter into negotiations. "Comprehend that the process might take a while as well as you'll should be relentless and person," claims Sobel. "Be sure that you've looked into all your funding choices beforehand, and know just how adaptable your terms are."
Making A Deal On A Home Ireland As might be expected, it is crucial that you provide information that is correct as well as do not devote mistake by omission, stopping working which you could well not be covered in event of insurance claim, or have the contract cancelled by insurer.
#Tennessee:t# Property Tax Calculator Throughout this procedure, a certified and also skilled house evaluator will check out the residence and assess it throughout. The evaluator will certainly then supply a quote of the buildings value in the present real estate market. The loan provider intends to ensure that the quantity being paid for the residential property reflects real market price.
Obtaining A Mortgage Lighthouse credit rating professionals deal with experts as well as solution participants completely free to craft a plan to boost their credit rating. The Lighthouse Program provides veterans with complimentary tools and information to help them improve their debt account as well as get on the roadway to financing prequalification.
You should likewise be planned for a bidding process situation. Some banks will certainly approve deals for a specific time period, after which they'll pick the highest bidder. In other instances, they will certainly contact all the potential buyers to let them understand a greater deal has actually been made. To puts it simply, they'll attempt to obtain the customers to outbid one another-- as well as therefore increase the price. This is why you should understand (A) what does it cost? they house is absolutely worth in the existing market, and also (B) how much you want to spend for it.


text:
Jason Klein
Author. Writer. Editor. Sports Blogger. Content Curator.
Here's The Catch: Posada Should Receive #602 From Mo
Posted on September 14, 2011 by ByJasonKlein
By Jason Klein
Follow @ByJasonKlein
Originally Written For Ed Randall's Talking Baseball – 9/13/11
Mariano Rivera is about to catch Trevor Hoffman. When he does, Jorge Posada is the right man to catch Rivera.
The immortal Rivera is just one save shy of 600, two away from joining Hoffman atop the all-time career saves list with 601, and three away from passing him with 602. After that, there will no doubt be more saves added to Rivera's first-ballot Hall of Fame resume – the ageless closer currently has a 2.09 ERA, and at age 41, looks as good as he ever has.
Posada Should Hand Ball To Rivera for #602/Getty Images
Perhaps prospects like Jesus Montero or Austin Romine will backstop Rivera's final career save, sometime in 2012 or beyond. That's for another day. When Rivera collects his 602nd career save, probably sometime in the next week or so, it should be Posada receiving the record-breaking, and no doubt devastating, cutter.
There is no one more fitting to do the honors.
For 13 seasons, from 1998-2010, Posada was a mainstay behind the plate for the Yankees. Although the switch-hitting catcher was always revered more for his abilities at the plate, rather than behind it, he certainly held his own defensively over the years. With the acquisition of Russell Martin, and up-and-comers Montero and Romine on the way, Posada was relegated to DH in 2011, getting the occasional start at first base.
He was also embarrassed twice, on national TV. First he was dropped to 9th in the line up on May 14th, and then he lost his DH job on August 7th – both prior to games with the Red Sox.
Iroinically, when injuries claimed Martin and back up Francisco Cervelli, Posada was thrown behind the plate for the first time all season on September 10th. However, the Yankees were so disenchanted with the 40-year-old catching, they called up the 22-year-old Romine the next day to take over.
Posada has lost a step, and this will most likely be his final season in pinstripes, but he deserves the opportunity to be a part of history with his battery mate, Rivera.
On July 9th, Posada was the first one to congratulate his long-time teammate Derek Jeter at home plate following his 3,000th career hit. For 13 seasons, Posada was the first to toast his closer, dropping the ball in his mitt, save after legendary save. He's certainly capable of catching one more inning – the ninth of course – during the record-breaking affair.
It's the right thing to do for a franchise obsessed with history and magical storylines. There's no question, the moment will belong to Rivera, but Posada should get to play a small part in the festivities.
"Enter Sandman" will fill the air as Rivera makes his iconic trot to the hill, in hot pursuit of history. The flashbulbs will be popping that night. It's only fair that Posada's glove is popping too.
Connect With Jason
This entry was posted in Talking Baseball and tagged Derek Jeter, Jorge Posada, Mariano Rivera, MLB, New York, Yankee Stadium, Yankees by ByJasonKlein. Bookmark the permalink.


text:
หน้าแรกLANXESSLANXESS Opens APAC Application Development Center in Shanghai
LANXESS Opens APAC Application Development Center in Shanghai
First project to start operation at the InnoGreen Shanghai International Chemical New Materials Innovation Center
Shanghai – June 18, 2021 – German specialty chemicals company LANXESS held the opening ceremony for its APAC Application Development Center (AADC) at Shanghai Chemical Industry Park (SCIP) on June 18.
LANXESS opened APAC Application Development Center in Shanghai.
Photo: LANXESS
The new center substantially increases the company's local innovation capabilities. Initially, it combines the research activities of the Business Units Polymer Additives (PLA), Lubricant Additives (LAB), and Urethane Systems (URE). The AADC is the first project put into operation at SCIP's new InnoGreen Shanghai International Chemical New Materials Innovation Center.
Ming Cheng Chien, President of the LANXESS APAC Region, opened the ceremony.
Ming Cheng Chien, President of LANXESS APAC Region, Thomas Triller, Acting Consul General of the Federal Republic of Germany in Shanghai, Shousheng Li, Chairman of China Petroleum and Chemical Industry Federation (CPCIF), Jing Ma, Director of Shanghai Chemical Industry Park Administration Commission (SCIPAC), and Dr. Anika van Aaken, Head of the AADC, were among those attending the ceremony. LANXESS Chairman of the Board of Management Matthias Zachert and Board Member Dr. Anno Borkowsky joined online.
"We are proud of being the first company to settle at the InnoGreen Shanghai International Chemical New Materials Innovation Center. The AADC will enhance our local innovation and strengthen our confidence in the Chinese market, and ultimately serve our customers in the entire Asia-Pacific region," said Ming Cheng Chien, President of LANXESS Asia Pacific.
"Today marks an important milestone in our history in China. Our operations here are central to our global strategy, and we are grateful for the long-term partnerships we have forged in this country," Matthias Zachert said in his speech. "China is a nation of opportunity, and we are always seeking new ways to support and participate in its growth and prosperity."
"This Application Development Center was built to strengthen our starting position to address several strategically vital markets," Dr. Anno Borkowsky said in his speech. "And being here only one year after the groundbreaking, we have done so with significant speed. With the AADC, we are taking another vital step towards being able to benefit from the growth potential in the world's largest chemical market."
German specialty chemicals company LANXESS held the Opening Ceremony for its APAC Application Development Center (AADC) at Shanghai Chemical Industry Park (SCIP).
The establishment of the AADC also underlines LANXESS' confidence in China's growth potential. As the world's largest chemical market, China already accounts for 40 percent of global chemical sales, and the figure will approach 50 percent by 2030.
To meet the growing market demand, LANXESS has increased its presence in China and enhanced its market position in the entire Asia-Pacific region through continuous investment. In 2018, the company launched a new regional setup in the Asia Pacific region, covering Greater China, Japan, South Korea and the ASEAN countries to promote synergies between countries and business units.
In September 2019, LANXESS signed an MOU with SCIP to set up an integrated site as a new base for sustainable growth in China. Two months later, the company announced its plan to establish a comprehensive application development center to strengthen its innovation capabilities in China and the Asia-Pacific region. This came as the need for localized product grades increased due to shifting demand toward value added products in China. In March 2020, LANXESS announced that the AADC would be located at SCIP. The delivery of the AADC building took place in December 2020.
Thanks to the continuous presence in China, the region was the only market with strong demand in the Asia-Pacific region during the pandemic. The sales in Greater China in 2020 accounted for 14 percent of LANXESS' total global sales.
About LANXESS
LANXESS is a leading specialty chemicals company with sales of EUR 6.1 billion in 2020. The company currently has about 14,200 employees in 33 countries. The core business of LANXESS is the development, manufacturing and marketing of chemical intermediates, additives, specialty chemicals and plastics. LANXESS is listed in the leading sustainability indices Dow Jones Sustainability Index (DJSI World and Europe) and FTSE4Good.
LANXESS China
On January 31, 2005, the company was initially listed on the Frankfurt Stock Exchange and LANXESS Chemical (China) Co., Ltd. officially started operations. LANXESS now has 13 subsidiaries, 6 R&D centers and 7 production sites with around 1,200 employees in Greater China. LANXESS works closely with its local partners to develop market-oriented solutions that meet local market needs.
This company release contains certain forward-looking statements, including assumptions, opinions, expectations and views of the company or cited from third party sources. Various known and unknown risks, uncertainties and other factors could cause the actual results, financial position, development or performance of LANXESS AG to differ materially from the estimations expressed or implied herein. LANXESS AG does not guarantee that the assumptions underlying such forward-looking statements are free from errors, nor does it accept any responsibility for the future accuracy of the opinions expressed in this presentation or the actual occurrence of the forecast developments. No representation or warranty (expressed or implied) is made as to, and no reliance should be placed on, any information, estimates, targets and opinions, contained herein, and no liability whatsoever is accepted as to any errors, omissions or misstatements contained herein, and accordingly, no representative of LANXESS AG or any of its affiliated companies or any of such person's officers, directors or employees accept any liability whatsoever arising directly or indirectly from the use of this document.
Business chemical EN LANXESS


Shhh... there is a not so secret brewery hiding in San Francisco and another must visit just outside.
The Day we got back from Chico our cousin brought us to to her local brewery named after the county she resides in which is Marin.
I should take this opportunity to thank our host for the trip, though I am not sure she reads. We will call her K. Well she is probably the nicest woman in the world and she moved out of her apartment while we were there so we could stay there. She either stayed with friends or her parents. We were staying in the Mill Valley area and her parents were in San Rafael, all of which is part of Marin County.
Anyway the Marin brewing Co has an interesting list of beers but also the food was fantastic. The location itself is actually brilliant too. From San Francisco you just jump on the ferry to Larkspur which in itself is a fantastic trip past Alcatraz and then with a good view of the California state prison complete with prisoners in the yard looking longingly down at you in the orange jumpsuits. It is amazing that Larkspur contains one of he countries most notorious prisons and has such a low crime rate. Anyway from the Larkspur ferry terminal you simply walk across the pedestrian bridge and you are at the brewery.
On a hot day you might want to sit outside in the large beer garden.
There was a nice sample tray on offer and there was not one beer I did not think was excellent, which was a nice change as so far there was always at least one and usually it was a Wit or Blonde. The only one I did not like too much was perfectly fine, I just found it too sweet as it was a Peach ale and I find a lot of fruit beers a little sweet unless they are a proper lambic style.
The two that stood out for me were the IPA which apart from being a fantastic California style IPA it was also earthy and a little herbal.
The other one was called Es'Chi which is a very interesting beer. It is an English style bitter that has had a special blend of Chinese herbs by a local Chinese medicine healer. I have to say I found this to be one of my favourite beers of the trip. It was certainly herbal but also smoky which just made it so interesting.
After Marin, since it was Friday I wanted to try and get to Speakeasy which was only open on Friday's to the public. Now I had said that I might have gone to Anchor as well but that did not happen. Anchor only opens on Friday as well but they are busy being taken over.
We arrived at about 3:45 in the afternoon to a conspicuous looking warehouse. This is all you see above, there is no mention of it being a brewery so unless you know already what the brand is you would have no idea although you might wonder at the growing number of people parking their cars and waiting because as it turns out the doors open at 4pm so we were there at the perfect time.
When you walk in first you go to a glass window and present your ID for age verification and then you give them money. It is actually very reasonable to be honest. For $10 I got a branded glass and two tokens that I can use for any two beers at the bar inside the warehouse.
I got one for me and one for my wife. I can't remember which one I had because I was too busy snooping to take any notes. I think I got the White lightning wit for my wife though.
Nice to see they recycle their spent grain.
Our host is explaining the filter system. I prefer unfiltered beer but I won't hold that against Speakeasy who make some fantastic beer.
You can actually have parties here, There is a disco ball on the roof and everything. Can you imagine a party in a brewery? With all these kegs waiting to be tapped?
They just have 25kg sacks of grain like I would use at home, although one 25kg sack does me for months and they would require a few per batch.
The bottling line is right in the warehouse.
I would have liked to see it in action but it was not to be but it looks impressive.
This was a very informative and fun brewery and the sort of brewery tour I had hoped to get in Sierra Nevada. It was up close and personal, you risk injury from tripping over brewery stuff and slipping in puddles of beer and one of the brewers guides you through, drink in hand and explains how it all works even though a lot of his audience are like me and brew themselves so know the process. Still it is nice to see how they do it themselves.
I like that the water they use for the wort chilling process is recirculated (as its hot) back in to the hot liquor tank for use as sparge water.
One thing to note on speakeasy is that it is not in the easiest place to get to by public transport but I did see a light rail nearby at the entrance to the industrial park.
The Tale Of The Ale: Shhh... there is a not so secret brewery hiding in San Francisco and another must visit just outside.


text:
Hungry for Attention
by J. Hoberman
Voice Choice
Berlin's story: Edie Falco in Babylon Shooting Gallery
One of the most-praised dramatic features of the 1999 Sundance Festival, Judy Berlin has intimations of soft apocalypse. Eric Mendelsohn's debut film is a carefully assembled, quasi-autobiographical mood-piece that, shot in meditative black and white, aspires to place a mid-Long Island suburb in the light of eternity. (Alas, Babylon—I knew it well.)
David Denby exhorted historically minded distributors to "seize the chance to be a part of Eric Mendelsohn's future" in his New Yorker Sundance report. Judy Berlin is, however, more a wistful look back at the artist's past. Not as caustic in his suburbanations as fellow SUNY Purchase grad Hal Hartley, Mendelsohn embodies his ambivalence in two thirtyish showbiz wannabes. The cheerfully crass aspiring actress Judy Berlin (Sopranos star Edie Falco) is finally leaving Long Island for L.A. even as her glum erstwhile classmate David Gold (Aaron Harnick) winds up back home, nursing some unrevealed psychic wound and dreaming of unmade movies.
Gently schematic, Judy Berlin unfolds on the afternoon of a total eclipse that—the cosmic clock having frozen—plunges Babylon and environs into hours of unscheduled darkness. It's a scenario for the end of the world but Mendelsohn's dramatic structure more suggests a class excursion to a petting zoo where a few harmless animals roam free. David's high-strung mother sings of being 16 again. (Making the most of her last screen role, Madeline Kahn gives her unstable character a poignant, strident edge.) Meanwhile a retired teacher in the early stages of memory loss revisits her old classroom and there causes a scene. Judy wanders around town saying her goodbyes; David merely wanders until the inevitable: "David Gold? This is so freaky!"
Mendelsohn is acute on the embarrassment of reencountering a high-school ghost some dozen years after graduation supposedly exorcised them all. He's less convincing on the chemistry that's meant to exist between these antithetical types. Judy's a gregarious extrovert, David's depressed and judgmental. The actors, perhaps encouraged to play dumb, overheat the connection until the movie blows a fuse. Harnick's morose theatricality serves to encourage Falco's wild face-pulling. She widens her eyes to accentuate her outsized features, flashing a foolish clown smile to show off her adult braces.
Drawn to Judy's vulgar energy, David visits the local History Village where she works as a colonial milkmaid, and together they experience the magical eclipse. David is still puzzled that Judy, who wears her costume throughout, was a high-school tough girl: "I mean—aren't you Jewish?" Less successful for being overly stagy, a parallel interaction involves David's father (Bob Dishy), the defensively dithering principal of the elementary school, and Judy's dourly officious mother (Barbara Barrie), who is a teacher there. Invoking a lifetime of might-have-beens, their scenes have a discordant Broadway polish. "Do you understand that I don't know what I'm doing?" he asks. Indeed, she does.
David, however, knows exactly what he's doing. His dark secret is that he has always yearned to make a documentary about daily life in an American suburb, something celebratory—"nothing sarcastic." This would-be symphony of the quotidian—the town lovingly photographed and dusted with sparkly harpsichord music—is his dream film. And, conveniently disappearing into the night, Judy is the bravely deluded muse who inspired him.
A bit precious, ultimately wearisome, Judy Berlin deserves to alternate reels with Lodge Kerrigan's even more pretentious Amerindie, Claire Dolan. Indeed, in a more perfect universe, Claire Dolan would be the feature in which Judy got her break.
Like Kerrigan's first feature, the genuinely disturbing Clean, Shaven (1993), Claire Dolan—opening for a week at the Walter Reade before its release by New Yorker Films—is a character study about an ostentatiously opaque character. The film is impeccably shot and utterly absurd. Superstudied telephoto compositions map a cold urban geometry of steel furniture and rippling reflections. Katrin Cartlidge, most familiar for her garrulous roles in Mike Leigh's Naked and Career Girls, has here been silenced, playing a high-class hooker who operates out of an East Side apartment with the charm of a dentist's waiting room.
Claire Dolan is hardly a slice of life. Once you buy into the idea of a call girl without a cell phone or even a beeper—when first seen, Claire is working a grimy midtown pay phone—anything is possible. Clients don't call her, she calls them, professing her desire and promising unimaginable pleasures in a flat monotone. Embodied by Cartlidge as dourly antierotic, she's gawky and severe, squinting balefully at her tricks as she's metaphorically nailed on the grid of a heartless city. In short, Claire (who owes money to her unctuously solicitous pimp until suddenly she doesn't) is an abstract entity.
Kerrigan's dialogue is as purposefully stilted as his mise-en-scène is aggressively antiseptic. This supremely alienated movie can't decide if it's Crash or Working Girls or maybe Jeanne Dielmann in reverse. Every interaction is tortuous—Claire's numerous sexual encounters not the least. At one point, she escapes to Newark, gets a new job, and picks up a sensitive cabbie named Elton (played by a smirking Vincent D'Onofrio as if without direction). Then, operating by some mysterious radar, her bluff, hearty pimp (Colm Meaney) comes to fetch her home, reinforcing his ruthlessness by casually tossing a pet kitty out the window.
Clean, Shaven demonstrated Kerrigan's intermittent brilliance. (Here, the movie jumps to life when Elton, in a scarily intense burst of adrenaline, is robbed in his cab.) But, even more than his heroine, the filmmaker seems boxed in by his own schemata. Less awful than inert, Claire Dolan comes across as a willfully bad movie. The moment of maximum stupefaction arrives when Claire affectlessly announces her desire. "I want to have a child," she abruptly informs Elton, adding without inflection, "we can make it work." Her conviction is underwhelming.
Those in search of an energy fix could do worse than Don McGlynn's Louis Prima: The Wildest, a big smoochy valentine to one of the most resilient American entertainers of the 20th century which, having had its local premiere at the Margaret Mead, opens a week from Friday at Cinema Village. Born in New Orleans, the wildly energetic Prima was a trumpet-playing, hoarse-voiced scat singer—a white disciple of Louis Armstrong (whom I don't believe the movie ever mentions). Discovered by Guy Lombardo in the '30s, Prima helped establish 52nd Street as a Dixieland mecca. He wrote the swing blockbuster "Sing, Sing, Sing," relocated to Hollywood, and dated Jean Harlow. A crony recalls his response to the actress's untimely death: "I think he was sad."
The movie is similarly taciturn on other biographical subjects, but Prima's call and response clowning has near universal appeal. Always looking for an audience, he recorded in Italian, played the Apollo, and made the transition from big-band swing to proto-rock 'n' roll. Most spectacularly, Prima reinvented himself as a Las Vegas hepcat, abetted by the impassive vocalist Keely Smith and frantic saxophonist Sam Butera. He was still limber enough to jump on the Twist and even provide Walt Disney with a star vocal turn in The Jungle Book. Nor was that the end. McGlynn's performance-rich doc appears to have been made too soon to acknowledge Prima's posthumous assist to the most successful Gap ad in history.
More:Eric MendelsohnFilm and TVFilm ReviewsJudy BerlinLodge KerriganLouis Prima


text:
Unforgettable est une chanson du rappeur marocain French Montana. Elle a été publiée par Epic Records et Bad Boy Records le  en tant que single principal de son deuxième album studio Jungle Rules en même temps que No Pressure. La chanson est interprétée par Swae Lee et a été produite par Jaegen and 1Mind. En France, la chanson s'est placée à la 9 place du classement. Aux États-Unis, elle s'est classée 3 du Billboard Hot 100, en faisant la première chanson de French Montana, en tant qu'artiste principal, à se classer dans le top 10, mais également la première de Swae Lee en tant qu'artiste solo.

Unforgettable a atteint le top 10 dans quinze pays, dont l'Australie, le Canada, le Danemark, l'Allemagne, l'Irlande, les Pays-Bas, la Nouvelle-Zélande, la Suède, la Suisse et le Royaume-Uni. La chanson a atteint le top 20 en Autriche, République tchèque, Hongrie, au Liban, en Norvège, Écosse et Espagne.

Historique

French Montana a d'abord sorti la chanson en  avec Swae Lee et Jeremih. La chanson a par la suite été remixée et masterisée pour sortir officiellement le single le  en même temps que No Pressure avec Future. Le single a été certifié disque de diamant et multi disque de platine and plus de seize pays, dont six fois disque de platine aux États-Unis par l'RIAA.

Composition

Unforgettable est une chanson dancehall et hip-hop. Selon la partition publiée sur musicnotes.com, la chanson est écrite en sol♯ mineur avec un tempo de 98 battements par minute.

Clip vidéo

Le clip vidéo accompagnant la chanson est sorti le  sur le compte Vevo de French Montana  sur YouTube. La vidéo a été tournée à Kampala en Ouganda. Elle a été réalisée par French Montana et Spiff TV. On y voit les Ghetto Kids, un groupe de jeunes danseurs ougandais. En , la vidéo compte plus d'un milliard de vues sur YouTube.

Reprises

Le , une version espagnole de la chanson est sortie, interprétée par le chanteur colombien J Balvin.

Il existe également un autre remix interprété par la chanteuse américaine Mariah Carey.

Le chanteur Akon a également fait une reprise pour la chanson Predictable dans la mixtape Konvict Kartel Vol. 2.

Utilisation dans les médias

La chanson a été utilisée dans l'épisode trois de la première saison de Grown-ish, ainsi que dans le film The After Party.

Liste des pistes

Téléchargement digital
Unforgettable (feat. Swae Lee) – 3:53
Unforgettable (feat. Swae Lee) [Clean] – 3:53
J Hus & Jae5 Remix
Unforgettable (J Hus & Jae5 Remix) (feat. Swae Lee) – 3:46
Major Lazer Remix
Unforgettable (Major Lazer Remix) (feat. Swae Lee) – 3:16
Latin Remix
Unforgettable (with J Balvin) (feat. Swae Lee) – 3:34
Unforgettable (with J Balvin) (feat. Swae Lee) [Clean] – 3:34
Tiësto & Dzeko's AFTR:HRS Remix
Unforgettable (Tiësto & Dzeko's AFTR:HRS Remix) (feat. Swae Lee) – 3:40
Mariah Carey Remix
Unforgettable (with Mariah Carey) (feat. Swae Lee) – 3:53
Unforgettable (with Mariah Carey) (feat. Swae Lee) [Clean] – 3:53
Unforgettable (with Mariah Carey) (Version acoustique) (feat. Swae Lee) – 4:04
Unforgettable (with Mariah Carey) (Version acoustique) (feat. Swae Lee) [Clean] – 4:04
Slushii Remix
Unforgettable (Slushii Remix) (feat. Swae Lee) – 3:07
Unforgettable (Slushii Remix) (feat. Swae Lee) [Clean] – 3:07

Classements

Classements hebdomadaires

Classements de fin d'année

Certifications

|-
! scope="row"|  (ZPAV)
|Platine
|20 000*
|-
! scope="row"|  (AFP)
|2× Platine
|20 000
|-

Source

Références

Single musical sorti en 2017
Single numéro un au UK Hip Hop and R&B Chart
Chanson de 2017
Clip vidéo ayant atteint le milliard de vues sur YouTube

redpajama_set_name: RedPajamaWikipedia


information you probably don't know about your body hair. This article will help give you some information about these tiny little hairs growing all over our body.
differentiate your ethnicity. There are different spectrums when it comes to ethnicities. With each ethnicities there are different amounts of terminal hair. Asians have the least amount of terminal hair, Hispanic and Middle Eastern ethnicities have the most. The res often fall in between. So, the normal amount of hair for you may be on a whole different scale for someone else.
grow back but the results aren't always permanent.
might even experience hair growth in your chin. This may seem awful, but it is a completely normal experience. Your hair will go back to normal after pregnancy of menopause.
If your experience hirsutism from your irregular periods, then this may be a systemic problem. This is often caused by polycystic ovary syndrome. This is when the enlarged ovaries contain fluid (follicles). The second cause of irregular periods and hirsutism can be obesity, which can also be related to polycystic ovary syndrome.
hair? Share it with us.


President Obama has been working to rally support from Americans, and it's working. Thousands gathered in downtown Washington to support his plan for healthcare reform.
About 5,000 people traveled from different parts of the country to participate in the march. Protesters criticized the health insurance industry and addressed increasing premiums. President Obama is citing such increases as the reason healthcare reform is desperately needed.
The rally comes at a time when Republicans warn that Americans don't want Obama's health bill to pass. Republican strategists have said that if Obama overhauls the system, Democrats will pay the consequences in the upcoming November midterm elections.
President Obama says he doesn't know how the move will play out politically but that Americans are waiting for lawmakers to finish what he started, end a year of legislative struggle and enact legislation ushering in near-universal medical insurance coverage for the first time in the country's history.
White House officials expect to pass the health bill by March 17th.